BANK VONTOBEL/CALL/NOVO NORDISK ADR B/150/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 14:02:43 2024-06-28 EDT | ||
| 1.07 EUR | -2.73% |
|
| Current month | +52.86% | ||
| 1 month | +48.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 1.07 | -2.73% |
| 24-06-27 | 1.1 | -.--% |
| 24-06-26 | 1.1 | -11.29% |
| 24-06-25 | 1.24 | +25.25% |
| 24-06-24 | 0.99 | -1.98% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 02:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD0HBH |
| ISIN | DE000VD0HBH7 |
| Date issued | 2024-02-16 |
| Strike | 150 $ |
| Maturity | 2024-12-20 (173 Days) |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.48 € |
| Spread | 0.01 € |
| Spread % | 0.96% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
